The CysLT1 receptor antagonist montelukast inhibits mast cell activation induced by inhaled leukotriene E4 in subjects with asthma
Use of Montelukast to Reduce Infusion Reactions in an Early Access Treatment Protocol of Daratumumab in United States Patients with Relapsed or Refractory Multiple Myeloma
Tags: allergies, asthma, CysLT1 antagonist, leukotriene receptor antagonist (LTRA), Singulair®
BASi Method Number SAP.1105
Sign up and you’ll receive the latest updates that matter to you, delivered straight to your inbox.
